Development of a human breast-cancer derived cell line stably expressing a Bioluminescence Resonance Energy Transfer (BRET)-based Phosphatidyl Inositol-3 Phosphate (PIP 3) biosensor

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Kuo, Mei Shiue ^a,b   Auriau, Johanna ^a,b   Pierre Eugène, Cécile ^a,b   Issad, Tarik ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; CETUXIMAB; EPIDERMAL GROWTH FACTOR; INSULIN; INSULIN GLARGINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RENILLA LUCIFERIN 2 MONOOXYGENASE; SOMATOMEDIN B; SOMATOMEDIN C; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; YELLOW FLUORESCENT PROTEIN;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BIOSENSOR; CELL CLONE; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION;

BIOLUMINESCENCE RESONANCE ENERGY TRANSFER TECHNIQUES; BIOSENSING TECHNIQUES; BREAST NEOPLASMS; CELL LINE, TUMOR; HUMANS; PHOSPHATIDYLINOSITOL PHOSPHATES;

EID: 84898618717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092737     Document Type: Article

References (61)

1. Combettes-Souverain M, Issad T (1998) Molecular basis of insulin action. Diabetes Metab 24: 477-489. (Pubitemid 29048416)
2. Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127-150.
3. Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, et al. (1993) Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 268: 9478-9483. (Pubitemid 23146000)
4. Leslie NR, Downes CP (2002) PTEN: The down side of PI 3-kinase signalling. Cell Signal 14: 285-295. (Pubitemid 34164684)
5. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
6. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, et al. (2010) Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One 5: e9646.
7. Fabre S, Lang V, Harriague J, Jobart A, Unterman TG, et al. (2005) Stable activation of phosphatidylinositol 3-kinase in the T cell immunological synapse stimulates Akt signaling to FoxO1 nuclear exclusion and cell growth control. J Immunol 174: 4161-4171. (Pubitemid 40395994)
8. Harriague J, Bismuth G (2002) Imaging antigen-induced PI3K activation in T cells. Nat Immunol 3: 1090-1096. (Pubitemid 35363663)
9. Pierre-Eugene C, Pagesy P, Nguyen TT, Neuillé M, Tschank G, et al. (2012) Effect of insulin analogues on Insulin/IGF1 hybrid receptors: Increased activation by glargine but not by its metabolites M1 and M2. PLoS One 7(7): e41992.
10. Kanwal S, Fardini Y, Pagesy P, N'Tumba-Byn T, Pierre-Eugène C, et al. (2013) O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-Tamoxifen in human breast cancer-derived MCF-7 cells. PLoS One 8(7): e69150: 9539-9544.
11. Blanquart C, Achi J, Issad T (2008) Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer. Biochem Pharmacol 76: 873-883.
12. Blanquart C, Karouri SE, Issad T (2009) Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem Biophys Res Commun 387: 748-753.
13. Liu JF, Issad T, Chevet E, Ledoux D, Courty J, et al. (1998) Fibroblast growth factor-2 has opposite effects on human breast cancer MCF-7 cell growth depending on the activation level of the mitogen-activated protein kinase pathway. Eur J Biochem 258: 271-276. (Pubitemid 28538332)
14. Issad T, Combettes M, Ferre P (1995) Isoproterenol inhibits insulin-stimulated tyrosine phosphorylation of the insulin receptor without increasing its serine/threonine phosphorylation. Eur J Biochem 234: 108-115.
15. Boute N, Pernet K, Issad T (2001) Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer. Mol Pharmacol 60: 640-645. (Pubitemid 32900244)
16. Lacasa D, Boute N, Issad T (2005) Interaction of the insulin receptor with the receptor-like protein tyrosine phosphatases PTPalpha and PTPepsilon in living cells. Mol Pharmacol 67: 1206-1213. (Pubitemid 40410420)
17. Nouaille S, Blanquart C, Zilberfarb V, Boute N, Perdereau D, et al. (2006) Interaction with Grb14 results in site-specific regulation of tyrosine phosphorylation of the insulin receptor. EMBO Rep 7: 512-518. (Pubitemid 43904868)
18. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, et al. (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 5: e9540.
19. Patil N, Abba M, Allgayer H (2012) Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics 6: 221-231.
20. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
21. Merlin JL, Barberi-Heyob M, Bachmann N (2002) In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol 13: 1743-1748. (Pubitemid 35439454)
22. Blanquart C, Boute N, Lacasa D, Issad T (2005) Monitoring the activation state of the insulin-like growth factor-1 receptor and its interaction with protein tyrosine phosphatase 1B using bioluminescence resonance energy transfer. Mol Pharmacol 68: 885-894. (Pubitemid 41206045)
23. Boubekeur S, Boute N, Pagesy P, Zilberfarb V, Christeff N, et al. (2011) A new highly efficient substrate-trapping mutant of protein tyrosine phosphatase 1B (PTP1B) reveals full autoactivation of the insulin receptor precursor. J Biol Chem 286: 19373-19380.
24. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
25. Miao B, Skidan I, Yang J, Lugovskoy A, Reibarkh M, et al. (2010) Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A 107: 20126-20131.
26. Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47: 209-217.
27. Fardini Y, Masson E, Boudah O, Ben Jouira R, Cosson C, et al. (2014) O-GlcNAcylation of FoxO1 in pancreatic beta cells promotes Akt inhibition through an IGFBP1-mediated autocrine mechanism. Faseb J 28: 1010-1021.
28. Zhang Y, Akhtar RA (1996) Effect of epidermal growth factor on phosphatidylinositol 3-kinase activity in rabbit corneal epithelial cells. Exp Eye Res 63: 265-275. (Pubitemid 26325116)
29. Jo H, Lo PK, Li Y, Loison F, Green S, et al. (2011) Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. Proc Natl Acad Sci U S A 108: 6486-6491.
30. Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD (2001) Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 276: 40080-40086.
31. de Cupis A, Noonan D, Pirani P, Ferrera A, Clerico L, et al. (1995) Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells. Br J Pharmacol 116: 2391-2400.
32. Roos W, Fabbro D, Kung W, Costa SD, Eppenberger U (1986) Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells. Proc Natl Acad Sci U S A 83: 991-995. (Pubitemid 16086399)
33. Imai Y, Leung CK, Friesen H, Shiu R (1982) Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. Cancer Res 42: 4394-4398. (Pubitemid 13205930)
34. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB (1994) Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Cancer Res 54: 4703-4709. (Pubitemid 24276498)
35. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, et al. (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52: 3924-3930.
36. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, et al. (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5: 1935-1944. (Pubitemid 29334478)
37. Soos MA, Field CE, Siddle K (1993) Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 290 (Pt 2): 419-426. (Pubitemid 23094937)
38. Blanquart C, Gonzalez-Yanes C, Issad T (2006) Monitoring the activation state of insulin/insulin-like growth factor-1 hybrid receptors using bioluminescence resonance energy transfer. Mol Pharmacol 70: 1802-1811.
39. Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen AS, Shaw AC, et al. (2006) Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem 281: 25869-25874. (Pubitemid 44401792)
40. Karey KP, Sirbasku DA (1988) Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res 48: 4083-4092.
41. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, et al. (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J 15: 2452-2467. (Pubitemid 26151185)
42. Kholodenko BN, Demin OV, Moehren G, Hoek JB (1999) Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 274: 30169-30181.
43. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, et al. (2006) Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem 281: 19925-19938. (Pubitemid 44065766)
44. Toyoshima Y, Kakuda H, Fujita KA, Uda S, Kuroda S (2011) Sensitivity control through attenuation of signal transfer efficiency by negative regulation of cellular signalling. Nat Commun 3: 743.
45. Tebbutt N, Pedersen MW, Johns TG (2013) Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 13: 663-673.
46. Martini M, Ciraolo E, Gulluni F, Hirsch E (2013) Targeting PI3K in Cancer: Any Good News? Front Oncol 3: 108.
47. Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, et al. (2009) In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res 69: 5073-5081.
48. Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, et al. (2010) The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ 17: 1795-1804.
49. Fortunati N, Catalano MG, Boccuzzi G, Frairia R (2010) Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol 316: 86-92.
50. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
51. Yang G, Ge H, Boucher A, Yu X, Li C (2004) Modulation of direct leptin signaling by soluble leptin receptor. Mol Endocrinol 18: 1354-1362. (Pubitemid 38692175)
52. Lahlou N, Issad T, Lebouc Y, Carel JC, Camoin L, et al. (2002) Mutations in the human leptin and leptin receptor genes as models of serum leptin receptor regulation. Diabetes 51: 1980-1985. (Pubitemid 34564314)
53. Symons JA, Eastgate JA, Duff GW (1991) Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 174: 1251-1254.
54. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854. (Pubitemid 35454590)
55. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, et al. (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28: 619-637. (Pubitemid 26174707)
56. Frost VJ, Helle SI, Lonning PE, van der Stappen JW, Holly JM (1996) Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 81: 2216-2221.
57. Panasiti V, Naspi A, Devirgiliis V, Curzio M, Roberti V, et al. (2011) Correlation between insulin-like growth factor binding protein-3 serum level and melanoma progression. J Am Acad Dermatol 64: 865-872.
58. Kuerzel GU, Shukla U, Scholtz HE, Pretorius SG, Wessels DH, et al. (2003) Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 19: 34-40. (Pubitemid 36378318)
59. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 33: 205-212. (Pubitemid 46863409)
60. Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, et al. (2012) Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 35: 2626-2630.
61. Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116: 73-78.